How Can Dermatological Laser Systems, Such As Co2 And Erbium Lasers, Be Effectively Utilized In Clinical Practice For Treating Actinic Keratosis (Ak) Lesions?

Dermatological lasers can treat selected actinic keratoses by precisely vaporizing abnormal tissue while limiting bleeding and collateral injury. CO₂ lasers are generally useful when strong hemostasis is important, including thicker, hyperkeratotic, or more vascular lesions. Erbium:YAG lasers provide cleaner, more superficial ablation with less thermal spread, making them valuable for delicate sites such as the face, scalp, lips, and actinic cheilitis.

The key is patient and lesion selection, not simply choosing the most powerful laser. CO₂ provides greater coagulation and hemostasis, while Er:YAG favors precision and minimal thermal damage. Both require controlled treatment depth, appropriate diagnosis, wound care, and follow-up for recurrent or suspicious lesions.

Where Laser Treatment Fits in AK Care

Confirm the lesion before ablating it

A lesion should be clinically assessed before laser treatment. Biopsy is important when the diagnosis is uncertain or when features suggest progression to squamous cell carcinoma, such as marked induration, ulceration, rapid growth, persistent tenderness, or an infiltrated base.

Laser ablation removes tissue and may eliminate the opportunity for histopathological assessment. Suspicious lesions should therefore be sampled or managed through an appropriate oncologic pathway rather than treated empirically.

Use laser selectively rather than routinely

Many AKs can be treated with cryotherapy, topical therapies, curettage, photodynamic therapy, or other established approaches. Laser treatment is particularly useful when a clinician needs precise ablation in a difficult location, treatment of a resistant hyperkeratotic lesion, or a blood-sparing technique.

Laser ablation can also be considered when conventional topical treatment is poorly tolerated, impractical, or ineffective. It should not replace field-directed treatment when multiple lesions and broader photodamage are present.

Choosing Between CO₂ and Erbium Lasers

When CO₂ is the better option

A CO₂ laser operates at approximately 10,600 nm, a wavelength strongly absorbed by water in tissue. It vaporizes the targeted tissue and produces an adjacent thermal coagulation zone.

This thermal effect can seal small blood vessels, offering useful hemostasis during treatment. CO₂ may therefore be advantageous for thicker, hyperplastic, or relatively vascular lesions and for patients in whom bleeding control is a significant concern.

The coagulative component can also produce collagen contraction and remodeling, although cosmetic goals should remain secondary to complete and appropriate lesion management.

When Er:YAG is the better option

Erbium:YAG lasers are also absorbed by tissue water but generally create less peripheral thermal damage than CO₂ systems. They are well suited to controlled, superficial ablation where preservation of surrounding tissue and reduction of thermal spread are priorities.

This makes Er:YAG attractive for less vascular lesions and delicate facial or lip procedures, including selected cases of actinic cheilitis. Reduced thermal injury may also help limit prolonged erythema, pigmentary change, and scarring risk, although these complications cannot be eliminated.

Match the device to the lesion and site

The decision should consider:

Lesion thickness and hyperkeratosis
Vascularity and expected bleeding
Anatomic location
Required ablation depth
Cosmetic importance of the treatment area
The patient’s healing capacity and medications

The most appropriate system is the one that achieves adequate lesion removal with the least unnecessary injury—not necessarily the system with the greatest energy output.

How to Use Ablative Lasers Effectively

Plan the treatment field

The clinician should identify the visible lesion and assess the surrounding skin for broader actinic damage. A sharply defined lesion may be treated focally, whereas diffuse photodamage may require a field-directed strategy rather than repeated spot ablation.

Small or hard-to-reach areas, including the nose, facial contours, scalp, and lips, can benefit from the precision and accessibility of a laser handpiece.

Control the ablation depth

The principal technical requirement is accurate depth control. The laser should remove the abnormal epidermal tissue while avoiding unnecessary penetration into the deeper dermis.

Excessive ablation increases the risk of delayed healing, scarring, pigmentary alteration, and prolonged inflammation. Insufficient ablation, on the other hand, can leave residual dysplastic tissue and contribute to persistence or recurrence.

Treatment parameters must therefore be individualized according to lesion thickness, location, device type, and the clinician’s assessment of the tissue response. Fixed settings should not be transferred from one lesion or device to another without clinical judgment.

Consider fractional CO₂ for selected field treatment

Fractional CO₂ systems create microscopic treatment zones separated by untreated skin. The remaining intact tissue can support faster epithelial regeneration and may reduce the burden of thermal injury compared with fully confluent ablation.

Fractional treatment may be useful when addressing broader areas of photodamaged skin, but it does not automatically ensure complete treatment of every AK. Visible, thick, or suspicious lesions may still require focused assessment and treatment.

Use laser-created channels as an adjunct when appropriate

Fractional ablative CO₂ treatment can create microscopic channels that increase penetration of subsequently applied topical agents or photosensitizers. In selected protocols, this may support combination treatment and improve delivery into damaged skin.

This is an adjunctive strategy, not a universal requirement. The topical agent, timing, and safety protocol must be specifically validated for the device and clinical indication.

Managing Special Clinical Situations

Patients taking anticoagulants

The coagulative effect of CO₂ can be helpful when treating patients receiving anticoagulant or antiplatelet therapy because it may reduce procedural bleeding. However, anticoagulant therapy should not be stopped solely to facilitate laser treatment without coordination with the prescribing clinician.

Bleeding risk, thrombotic risk, lesion location, and the planned depth of treatment must all be considered. Laser hemostasis reduces one procedural concern but does not remove the need for individualized medical assessment.

Hyperkeratotic or treatment-resistant lesions

Thick, hyperkeratotic AKs may respond poorly to topical medication because the keratin layer limits penetration. Controlled ablation can physically remove this barrier and the abnormal superficial tissue.

A resistant lesion should not simply receive progressively deeper laser treatment without reassessment. Persistence may indicate inadequate treatment, an incorrect diagnosis, or an underlying invasive process requiring biopsy.

Facial and lip lesions

Facial skin and the vermilion border are cosmetically and functionally sensitive. Er:YAG may be favored when minimal thermal spread and precise superficial removal are important, while CO₂ may be selected when additional coagulation is needed.

Actinic cheilitis often reflects broader sun damage rather than a single isolated spot. Treatment planning should therefore include examination of the entire lip and consideration of recurrence monitoring.

Understanding the Trade-offs

Laser is not automatically superior to standard therapy

Laser ablation can be highly precise, but it requires specialized equipment, trained operators, appropriate eye protection, and careful postoperative management. It may also be less suitable than simpler treatments for numerous superficial lesions.

The best treatment depends on lesion number, thickness, distribution, patient preference, available expertise, and the need for histology.

Hemostasis and tissue preservation involve a trade-off

CO₂’s thermal coagulation improves hemostasis but can increase collateral thermal injury if treatment is too aggressive. Er:YAG limits thermal spread but may provide less coagulation and may require more attention to bleeding control.

This is the central device-selection trade-off: CO₂ prioritizes coagulation and depth control; Er:YAG prioritizes clean superficial ablation and tissue preservation.

Recurrence and field cancerization remain concerns

Removing a visible AK does not reverse the patient’s underlying cumulative ultraviolet exposure. New lesions can develop in the same treatment field, and treated areas require ongoing surveillance.

Laser treatment should therefore be combined with sun protection, periodic skin examinations, and—when appropriate—management of surrounding actinic damage.

Healing and scarring risks must be explained

Possible adverse effects include pain, erythema, crusting, infection, delayed healing, pigmentary changes, and scarring. These risks increase with excessive depth, aggressive settings, poor wound care, and treatment of anatomically sensitive areas.

Patients should receive clear instructions on cleansing, moisture control, sun avoidance, and signs of infection or abnormal healing.

How to Apply This to Clinical Practice

Laser treatment is most effective when integrated into a structured diagnostic and follow-up pathway.

If your primary focus is precise treatment of a small or difficult lesion: Consider focal ablative laser therapy after confirming the diagnosis, with depth tailored to the lesion and location.
If your primary focus is hemostasis: CO₂ may be preferable for thicker, hyperplastic, or more vascular lesions, including selected patients in whom bleeding control is important.
If your primary focus is minimizing thermal injury: Consider Er:YAG for superficial or delicate facial and lip procedures where tissue preservation and cosmetic control are priorities.
If your primary focus is broad photodamage: Evaluate fractional CO₂ or another field-directed approach, while recognizing that individual thick or suspicious lesions may still require focused treatment or biopsy.
If your primary focus is preventing recurrence: Combine lesion treatment with ultraviolet protection, surveillance, and appropriate management of the surrounding actinically damaged skin.

Used with disciplined diagnosis, controlled ablation, and long-term surveillance, CO₂ and Er:YAG lasers can provide a precise and clinically valuable option for selected actinic keratoses.

Summary Table:

Laser Type	Wavelength	Key Advantage	Ideal Use Case
CO2	10,600 nm	Strong hemostasis and coagulation	Thicker, hyperkeratotic, vascular lesions
Er:YAG	2940 nm	Minimal thermal damage, precise superficial ablation	Delicate facial/lip areas, superficial lesions

Elevate your clinic's AK treatment capabilities with BELIS's advanced dermatological laser systems. Our CO2 and Erbium lasers offer precision, hemostasis, and safety for your patients. Partner with a trusted manufacturer for OEM/ODM support and certified quality. Contact us today to learn how our solutions can enhance your practice and profitability.